title: Oral Rivaroxaban for the Treatment of Symptomatic Venous Thromboembolism in 400 Patients With Active Cancer: A Single-Center Experience.
abstract: OBJECTIVE
  To study the safety and efficacy of rivaroxaban-a direct oral anticoagulant-use in patients with active cancer and venous thromboembolism (VTE).
  
  
  METHODS
  Retrospective cohort study of 400 patients with active cancer and associated VTE, defined as deep venous thrombosis and/or pulmonary embolism. This single-center study was carried out from January 2012 to June 2015. The aim of this study was to determine the efficacy and safety, using the incidence of recurrent symptomatic VTE and major bleeding, respectively, throughout the treatment with rivaroxaban.
  
  
  RESULTS
  Of the 400 patients enrolled, 223 (55.8%) were female. A total of 362 (90.5%) patients had solid tumors and 244 (61%) had metastatic disease. A total of 302 (75.5%) received initial parenteral therapy with enoxaparin (median: 3, mean: 5.6, standard deviation [SD]: 6.4 days) followed by rivaroxaban. Ninety-eight patients (24.5%) were treated with on label rivaroxaban treatment. Recurrence rates were 3.25% with major bleeding occurring in 5.5% during the anticoagulant therapy (median: 118, mean: 163.9, SD: 159.9 days).
  
  
  CONCLUSIONS
  Rivaroxaban can be an attractive alternative for the treatment of cancer-associated thrombosis.
authors.affiliation: 1 Vascular and Endovascular Surgery, AC Camargo Cancer Center, São Paulo, Brazil.
authors.forename: Bruno Soriano
authors.initials: BS
authors.lastname: Pignataro
authors.affiliation: 1 Vascular and Endovascular Surgery, AC Camargo Cancer Center, São Paulo, Brazil.
authors.forename: Kenji
authors.initials: K
authors.lastname: Nishinari
authors.affiliation: 1 Vascular and Endovascular Surgery, AC Camargo Cancer Center, São Paulo, Brazil.
authors.forename: Rafael Noronha
authors.initials: RN
authors.lastname: Cavalcante
authors.affiliation: 1 Vascular and Endovascular Surgery, AC Camargo Cancer Center, São Paulo, Brazil.
authors.forename: Guilherme
authors.initials: G
authors.lastname: Centofanti
authors.affiliation: 1 Vascular and Endovascular Surgery, AC Camargo Cancer Center, São Paulo, Brazil.
authors.forename: Guilherme
authors.initials: G
authors.lastname: Yazbek
authors.affiliation: 1 Vascular and Endovascular Surgery, AC Camargo Cancer Center, São Paulo, Brazil.
authors.forename: Mariana
authors.initials: M
authors.lastname: Krutman
authors.affiliation: 1 Vascular and Endovascular Surgery, AC Camargo Cancer Center, São Paulo, Brazil.
authors.forename: Guilherme Andre Zotelle
authors.initials: GAZ
authors.lastname: Bomfim
authors.affiliation: 1 Vascular and Endovascular Surgery, AC Camargo Cancer Center, São Paulo, Brazil.
authors.forename: Igor Yoshio Imagawa
authors.initials: IYI
authors.lastname: Fonseca
authors.affiliation: 1 Vascular and Endovascular Surgery, AC Camargo Cancer Center, São Paulo, Brazil.
authors.forename: Marcelo Passos
authors.initials: MP
authors.lastname: Teivelis
authors.affiliation: 1 Vascular and Endovascular Surgery, AC Camargo Cancer Center, São Paulo, Brazil.
authors.forename: Nelson
authors.initials: N
authors.lastname: Wolosker
authors.affiliation: 1 Vascular and Endovascular Surgery, AC Camargo Cancer Center, São Paulo, Brazil.
authors.forename: Solange Moraes
authors.initials: SM
authors.lastname: Sanches
authors.affiliation: 2 Vascular and Endovascular Surgery, Hospital Israelita Albert Einstein-São Paulo, São Paulo, Brazil.|3 Vascular and Endovascular Surgery, Loyola University Medical Center, Maywood, IL, USA.
authors.forename: Eduardo
authors.initials: E
authors.lastname: Ramacciotti
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D017984:Enoxaparin; D005260:Female; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000150:complications* / Q000473:pathology; D012008:Recurrence; D012189:Retrospective Studies; D000069552:Rivaroxaban / Q000008:administration & dosage*; D016896:Treatment Outcome; D054556:Venous Thromboembolism / Q000150:complications / Q000188:drug therapy*; D055815:Young Adult
chemical_list: D017984:Enoxaparin; D000069552:Rivaroxaban
keywords: cancer; oral anticoagulants; venous thrombosis